Navigation Links
Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
Date:12/5/2007

LEXINGTON, Mass., Dec. 5 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced the Company will be presenting at the RBC Capital Markets Conference on Thursday, December 13, 2007 at 12:30 PM Eastern Time. The conference is being held in New York City. The presentation will be web cast live and may be accessed by visiting the Investors section of the Indevus website at http://www.indevus.com.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) XR and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Co
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
(Date:4/17/2014)... improves general blood flow and alleviates muscle soreness ... at the University of Illinois at Chicago. , ... in the Archives of Physical Medicine and ... function in people who had not exercised, suggesting ... their level of physical activity. , Improved circulation ...
(Date:4/17/2014)... they suffer a cardiac arrest outside of a hospital ... to new research conducted at St. Michael,s Hospital. , ... arrest get adrenaline, which has been the drug recommended ... Lin, an emergency physician and trauma team leader at ... survival rates of patients who suffer a cardiac outside ...
(Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
(Date:4/16/2014)... 16, 2014 According to a new study, endoscopists, ... with one to two small polyps are consistent with ... may be an appropriate target for quality indicators. This ... adherence to guidelines for timing of repeat colonoscopy after ...
Breaking Medicine News(10 mins):Health News:New MRSA superbug emerges in Brazil 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3
... EAGAN, Minn., Feb. 9 Blue Cross and Blue Shield of Minnesota ... manager of the largest database of vendored disease management programs. The awards ... reducing adverse health events for its members. Blue Cross, disease management efforts ... diabetes , ...
... Equips Participants with Tools to Live Healthy, Active LivesCLEVELAND, ... Clinic has consistently sought to shift the national focus ... part of this commitment , Cleveland Clinic has ... helps reverse and decrease the effects of several common ...
... boosts well-being, study suggests, , , MONDAY, Feb. 9 (HealthDay ... buy happiness, purchasing life experiences instead of material possessions ... a study that asked more than 150 older college ... them happy, researchers found that people were more satisfied ...
... the Top Achievements in 50 Years of Women,s Health RARITAN, ... globulin product, celebrates its 40th year in the marketplace helping ... Newborn (HDN). In 1968, a new mother at Holy ... initial recipient of the world,s first injectable treatment to prevent ...
... intended to prevent HIV infection in women has demonstrated ... in Africa and the United States. Findings of the ... Allergy and Infectious Diseases (NIAID), part of the NIH, ... Opportunistic Infections in Montreal. , The study investigators ...
... Cancer Research Center have discovered a mechanism in liver metabolism ... in severe metabolic disorders. Mice suffering from metabolic syndrome or ... called LSR in the liver, as reported by researchers headed ... As a result, only small amounts of fat are ...
Cached Medicine News:Health News:Blue Cross Receives Disease Management Awards 2Health News:Blue Cross Receives Disease Management Awards 3Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 2Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 3Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 4Health News:Experiences Bring More Joy Than Possessions Do 2Health News:Experiences Bring More Joy Than Possessions Do 3Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 2Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 3Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 4Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 5Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 6Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 7Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 8Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 9Health News:Anti-HIV gel shows promise in large-scale study in women 2Health News:Anti-HIV gel shows promise in large-scale study in women 3Health News:Anti-HIV gel shows promise in large-scale study in women 4Health News:Pathologically elevated blood fat levels in obesity: Researchers discover molecular causes 2
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... 11, 2011 Conatus Pharmaceuticals Inc. today announced the ... private placement financing.  This financing was led by new ... participation by existing investors; Aberdare Ventures, Advent Venture Partners, ... Fund.  Conatus will use the proceeds to advance the ...
... 2011 Stryker Corporation,s (NYSE: SYK ) ... 510(k) clearance for its MDM X3 Modular Dual Mobility ... to the company,s portfolio of next-generation technologies designed to ... and address a broader patient population, including both primary ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 3
... CDI creates a smoother fit in the ... patient. The padded continuous hook and eye ... and the extra strong, yet very thin ... as a reinforced open crotch, gripper lace ...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
Short Girdle, Mid-thigh, Front Closure...
Medicine Products: